Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Fennec Pharmaceuticals (FENC) over the last 15 years, with Sep 2025 value amounting to -$623,000.

  • Fennec Pharmaceuticals' Net Income towards Common Stockholders rose 89.09% to -$623,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year decrease of 588.35%. This contributed to the annual value of -$436,000 for FY2024, which is 97.28% up from last year.
  • As of Q3 2025, Fennec Pharmaceuticals' Net Income towards Common Stockholders stood at -$623,000, which was up 80.25% from -$3.2 million recorded in Q2 2025.
  • Over the past 5 years, Fennec Pharmaceuticals' Net Income towards Common Stockholders peaked at $12.9 million during Q1 2024, and registered a low of -$10.3 million during Q4 2022.
  • For the 3-year period, Fennec Pharmaceuticals' Net Income towards Common Stockholders averaged around -$1.9 million, with its median value being -$2.6 million (2023).
  • Over the last 5 years, Fennec Pharmaceuticals' Net Income towards Common Stockholders had its largest YoY gain of 316.58% in 2024, and its largest YoY loss of 222.47% in 2024.
  • Quarterly analysis of 5 years shows Fennec Pharmaceuticals' Net Income towards Common Stockholders stood at -$4.2 million in 2021, then crashed by 89.66% to -$10.3 million in 2022, then spiked by 74.66% to -$2.6 million in 2023, then soared by 42.67% to -$1.5 million in 2024, then surged by 89.09% to -$623,000 in 2025.
  • Its Net Income towards Common Stockholders was -$623,000 in Q3 2025, compared to -$3.2 million in Q2 2025 and -$1.2 million in Q1 2025.